Literature DB >> 9367954

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

E S Rosenberg1, J M Billingsley, A M Caliendo, S L Boswell, P E Sax, S A Kalams, B D Walker.   

Abstract

Virus-specific CD4+ T helper lymphocytes are critical to the maintenance of effective immunity in a number of chronic viral infections, but are characteristically undetectable in chronic human immunodeficiency virus-type 1 (HIV-1) infection. In individuals who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4+ T cell proliferative responses were present, resulting in the elaboration of interferon-gamma and antiviral beta chemokines. In persons with chronic infection, HIV-1-specific proliferative responses to p24 were inversely related to viral load. Strong HIV-1-specific proliferative responses were also detected following treatment of acutely infected persons with potent antiviral therapy. The HIV-1-specific helper cells are likely to be important in immunotherapeutic interventions and vaccine development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367954     DOI: 10.1126/science.278.5342.1447

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  541 in total

1.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Specific therapy regimes could lead to long-term immunological control of HIV.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

3.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

4.  Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Authors:  M Dalod; M Dupuis; J C Deschemin; C Goujard; C Deveau; L Meyer; N Ngo; C Rouzioux; J G Guillet; J F Delfraissy; M Sinet; A Venet
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Authors:  T W Chun; J S Justement; S Moir; C W Hallahan; L A Ehler; S Liu; M McLaughlin; M Dybul; J M Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

6.  Cytotoxic T-lymphocyte memory, virus clearance and antigenic heterogeneity.

Authors:  D Wodarz
Journal:  Proc Biol Sci       Date:  2001-02-22       Impact factor: 5.349

Review 7.  A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment.

Authors:  D Wodarz; K M Page; R A Arnaout; A R Thomsen; J D Lifson; M A Nowak
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

Review 8.  Proving HIV-1 immunity: new tools offer new opportunities.

Authors:  L J Picker
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

9.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

10.  Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen.

Authors:  J C de Quiros; W L Shupert; A C McNeil; J C Gea-Banacloche; M Flanigan; A Savage; L Martino; E E Weiskopf; H Imamichi; Y M Zhang; J Adelsburger; R Stevens; P M Murphy; P A Zimmerman; C W Hallahan; R T Davey; M Connors
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.